Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | TNF | P01375 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627158 | 0.86 | SMN1; SMN2 (0.46) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL19911325 | 0.86 | FGFR1 (0.50) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL14446372 | 0.84 | ALDH1A1 (0.51) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL23638276 | 0.83 | TNF (0.46) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL12767952 | 0.83 | POLB (0.66) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL9570452 | 0.81 | TNF (0.47) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL12026868 | 0.81 | TNF (0.47) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL29749615 | 0.81 | SMN1; SMN2 (0.55) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL18136604 | 0.81 | LMNA (0.53) | CYP11B1CYP11B2LMNASMN1; SMN2HTT | |
| SCHEMBL15345063 | 0.80 | CYP11B1 (0.68) | CYP11B1CYP11B2LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | CYP11B1 640/4885CYP11B2 607/4885LMNA 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.